Conditions: Influenza
Keywords: Influenza Immunocompromised Antiviral
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 7
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the safety and tolerability of triple combination antiviral drug (TCAD) for use in immunocompromised patients with Influenza A infection, and to gain data on the effectiveness of TCAD

Detailed description:

Arms:
arm 1: TCAD (amantadine hydrocholoride, ribavirin and oseltamivir phosphate) arm 2: Zanamivir or Oseltamivir arm 3: TCAD for subjects who cannot tolerate or are ineligible to receive zanamivir

Interventions: intervention 1: TCAD intervention 2: Zanamivir or Oseltamivir intervention 3: Open label treatment with TCAD
Intervention descriptions: intervention 1: TCAD (amantadine hydrocholoride, ribavirin and oseltamivir phosphate) intervention 2: Zanamivir or Oseltamivir intervention 3: TCAD(amantadine hydrocholoride, ribavirin and oseltamivir phosphate)

Protocol document: